DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Off Label Use - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Off Label Use (88)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include off label use. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 88   Next >>

Possible Vincristine side effects in 43 year old female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-27

Patient: 43 year old female

Reactions: Off Label Use, Blindness

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin Hydrochloride

Etoposide

Ifosfamide

Vincristine



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin Hydrochloride
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Doxorubicin HCL
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin HCL
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Off Label Use, Zygomycosis

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses

Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses

Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
    Administration route: Oral

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
    Administration route: Oral

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
    Administration route: Oral

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1

Hydrocortisone
    Dosage: on days 8, 15 and 22

Hydrocortisone
    Dosage: on days 8, 15 and 22

Hydrocortisone
    Dosage: on days 8, 15 and 22

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement

Methotrexate
    Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement

Methotrexate
    Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in female

Reported by a physician from United States on 2012-08-20

Patient: female, weighing 70.8 kg (155.8 pounds)

Reactions: Abdominal Pain, Hyperpyrexia, Anaphylactic Reaction, Chills, Pain, Hepatic Failure, Transaminases Increased, Splenic Infarction, Loss of Consciousness, Aortic Thrombosis, Off Label Use, Malaise, C-Reactive Protein Increased, Myositis, Dyspnoea, Hypotension, Arrhythmia, Lung Consolidation, Hypophosphataemia, Zygomycosis, Bacteraemia, Ventricular Tachycardia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Shock, Infusion Related Reaction

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Cytarabine
    Dosage: day 1,8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23

Decadron Phosphate
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23

Doxil
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Methotrexate
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2005-01-01
    End date: 2007-01-01

PEG-Asparaginase
    Dosage: day 2, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-25
    End date: 2007-10-25

Velcade
    Dosage: day 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23

Vincristine
    Dosage: day 1,8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2007-10-23
    End date: 2007-10-23



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Off Label Use, Sepsis, Cerebral Ischaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: on day 1 over 15-30 minutes
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-17

Patient:

Reactions: Off Label Use, Hypoxia, Pleural Effusion, Bacterial Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Asparaginase
    Dosage: (pegylated) 2500 units/ m2/ dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: on days 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 and as cns involvement on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 and triple therapy on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: by push day 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-17

Patient:

Reactions: Off Label Use, Hypoxia, Bacterial Sepsis

Drug(s) suspected as cause:
Bortezomib
    Dosage: push on days 1, 4, 8, and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: day 1 with no cns involvement + on days 8, 15 + 22 with cns involvement
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses for 14 consecutive days from day 1
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: who had no cns involvement- day 15;
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: pegylated 2500 units/m2/dose given intravenously as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: by push (2 mg maximum dose) was administered intravenously by push day 1, 8, 15, and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-17

Patient:

Reactions: Off Label Use, Zygomycosis

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses

Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses

Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
    Administration route: Oral

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
    Administration route: Oral

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
    Administration route: Oral

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1

Hydrocortisone
    Dosage: on days 8, 15 and 22

Hydrocortisone
    Dosage: on days 8, 15 and 22

Hydrocortisone
    Dosage: on days 8, 15 and 22

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement

Methotrexate
    Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement

Methotrexate
    Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Peripheral Sensorimotor Neuropathy

Drug(s) suspected as cause:
Bortezomib
    Dosage: by push per dose on days 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: per day divided into 2 doses was given orally for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: 2500 units/m2/dose was given intramuscularly as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: per dose (2 mg maximum dose) was administered intravenously by push on day 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Hypotension, Hypertension

Drug(s) suspected as cause:
Bortezomib
    Dosage: per dose on days 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: per day divided into 2 doses was given orally for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: 2500 units/m2/dose was given intramuscularly as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: per dose (2 mg maximum dose) was administered intravenously by push on day 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Encephalopathy, Adrenal Insufficiency

Drug(s) suspected as cause:
Bortezomib
    Dosage: by push on days 1, 4, 8, and 11.
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses was given orally for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: 2500 units/m2/dose was given as 4 weekly doses.
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 2 mg maximum dose by push on day 1, days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Coagulopathy, Lower Gastrointestinal Haemorrhage, Escherichia Sepsis

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Amylase Abnormal, Lipase Abnormal

Drug(s) suspected as cause:
Bortezomib
    Dosage: per dose on days 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses was given orally for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: 2500 units/m2/dose was given intramuscularly as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: per dose (2 mg maximum dose) was administered intravenously by push on day 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Voriconazole; Vancomycin; Levofloxacin; Posaconazole



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Hyperglycaemia, Hypoglycaemia

Drug(s) suspected as cause:
Bortezomib
    Dosage: per dose on days 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: per day divided into 2 doses was given orally for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: 2500 units/m2/dose was given intramuscularly as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: per dose (2 mg maximum dose) was administered intravenously by push on day 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Hypoxia, Bacterial Sepsis

Drug(s) suspected as cause:
Bortezomib
    Dosage: push on days 1, 4, 8, and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: day 1 with no cns involvement + on days 8, 15 + 22 with cns involvement
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses for 14 consecutive days from day 1
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: who had no cns involvement- day 15;
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: pegylated 2500 units/m2/dose given intravenously as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: by push (2 mg maximum dose) was administered intravenously by push day 1, 8, 15, and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Amylase Abnormal, Lipase Abnormal

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: on day 1 over 15-30 minutes
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Encephalopathy, Cerebral Ischaemia

Drug(s) suspected as cause:
Bortezomib
    Dosage: on day 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 and on days 8, 15 and 22 (triple therapy)
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses for 14 consecutove days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 and on days 8, 15 and 22 for triple therapy)
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: 2500 units/m2/dose as weekly 4 doses
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 2mg maximum dose on day1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Encephalopathy, Cerebral Ischaemia

Drug(s) suspected as cause:
Bortezomib
    Dosage: per dose on days 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses was given orally for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 or days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Dosage: 2500 units/m2/dose was given intramuscularly as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: per dose (2 mg maximum dose) was administered intravenously by push on day 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Off Label Use, Hypernatraemia

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: on days 1, 4, 8, and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses was given orally for 14 consecutive days.
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: day 1
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: (2 mg maximum dose) was administeredintravenously by push day 1, 8, 15, and 22
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Voriconazole; Posaconazole; Levofloxacin; Vancomycin



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-14

Patient:

Reactions: Off Label Use, Bacterial Sepsis, Pleural Effusion, Hypoxia

Adverse event resulted in: death

Drug(s) suspected as cause:
Asparaginase
    Dosage: (pegylated) 2500 units/ m2/ dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: on days 1, 4, 8 and 11
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 and as cns involvement on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: divided into 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: on day 15 and triple therapy on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: by push day 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-08

Patient:

Reactions: Off Label Use, Bone Sarcoma

Drug(s) suspected as cause:
Etoposide
    Dosage: monthly cycle of 5 mg/kg daily for 2 days or 6 mg/kg daily for 2 days. total 6 cycles
    Indication: Retinoblastoma

Paraplatin
    Dosage: 18.6 mg/kg once or 14 mg/kg daily x 2 days, monthly cycle. total 6 cycles
    Indication: Retinoblastoma

Vincristine
    Dosage: 0.05 mg/kg once. monthly cycle. received total 6 cycles
    Indication: Retinoblastoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-08

Patient:

Reactions: Off Label Use, Bone Sarcoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Etoposide
    Dosage: monthly cycle of 5 mg/kg daily for 2 days or 6 mg/kg daily for 2 days. total 6 cycles
    Indication: Retinoblastoma

Paraplatin
    Dosage: 18.6 mg/kg once or 14 mg/kg daily x 2 days, monthly cycle. total 6 cycles
    Indication: Retinoblastoma

Vincristine
    Dosage: 0.05 mg/kg once. monthly cycle. received total 6 cycles
    Indication: Retinoblastoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-08

Patient:

Reactions: Off Label Use, Acute Promyelocytic Leukaemia

Drug(s) suspected as cause:
Etoposide
    Dosage: monthly cycle of 5 mg/kg daily for 2 days or 6 mg/kg daily for 2 days. total 6 cycles
    Indication: Retinoblastoma

Paraplatin
    Dosage: 18.6 mg/kg once or 14 mg/kg daily x 2 days, monthly cycle. total 6 cycles
    Indication: Retinoblastoma

Vincristine
    Dosage: 0.05 mg/kg once. monthly cycle. received total 6 cycles
    Indication: Retinoblastoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-08

Patient:

Reactions: Off Label Use, Bone Sarcoma

Drug(s) suspected as cause:
Etoposide
    Dosage: monthly cycle of 5 mg/kg daily for 2 days or 6 mg/kg daily for 2 days. total 6 cycles
    Indication: Retinoblastoma

Paraplatin
    Dosage: 18.6 mg/kg once or 14 mg/kg daily x 2 days, monthly cycle. total 6 cycles
    Indication: Retinoblastoma

Vincristine
    Dosage: 0.05 mg/kg once. monthly cycle. received total 6 cycles
    Indication: Retinoblastoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-08

Patient:

Reactions: Off Label Use, Malignant Melanoma, Rhabdomyosarcoma

Drug(s) suspected as cause:
Etoposide
    Dosage: monthly cycle of 5 mg/kg daily for 2 days or 6 mg/kg daily for 2 days. total 6 cycles
    Indication: Retinoblastoma

Paraplatin
    Dosage: 18.6 mg/kg once or 14 mg/kg daily x 2 days, monthly cycle. total 6 cycles
    Indication: Retinoblastoma

Vincristine
    Dosage: 0.05 mg/kg once. monthly cycle. received total 6 cycles
    Indication: Retinoblastoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-08

Patient:

Reactions: Off Label Use, Glioma

Drug(s) suspected as cause:
Etoposide
    Dosage: monthly cycle of 5 mg/kg daily for 2 days or 6 mg/kg daily for 2 days. total 6 cycles
    Indication: Retinoblastoma

Paraplatin
    Dosage: 18.6 mg/kg once or 14 mg/kg daily x 2 days, monthly cycle. total 6 cycles
    Indication: Retinoblastoma

Vincristine
    Dosage: 0.05 mg/kg once. monthly cycle. received total 6 cycles
    Indication: Retinoblastoma



Possible Vincristine side effects in 24 year old male

Reported by a physician from Norway on 2012-07-31

Patient: 24 year old male

Reactions: Off Label Use, Osteonecrosis

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 10 000iu d8 q22d

Cyclophosphamide
    Dosage: 650 (standard) or 1250 (escalated) mg/m2 d1 q22d

Doxorubicin Hydrochloride
    Dosage: 25 (standard) or 35 (escalated) mg/m2 d1 q22d

Etoposide
    Dosage: 100 (standard) or 200 (escalated) mg/m2 d1-3 q22d

Prednisolone
    Dosage: 40 mg/m2 d1-14 q22d
    Administration route: Oral

Procarbazine Hydrochloride
    Dosage: 100 mg/m2 d1-7 q22d
    Administration route: Oral

Vincristine
    Dosage: 1.4 mg/m2 d8 q22d

Other drugs received by patient: Sulfamethoxazole and Trimethoprim



Possible Vincristine side effects in female

Reported by a physician from Lebanon on 2012-07-20

Patient: female

Reactions: Off Label Use, Cytomegalovirus Chorioretinitis

Drug(s) suspected as cause:
Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide

Cyclophosphamide
    Dosage: total dose limited to 4.6 g/m2
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Cytarabine

Daunorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 4 doses of 5 g/m2
    Indication: Acute Lymphocytic Leukaemia

Prednisone
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017